IP Library › Granted Patent US 12,208,070
Granted Patent B2
US 12,208,070 · App. 18/317,654 · Granted Jan 28, 2025

Compositions containing dofetilide and mexiletine and uses thereof

Inventors: Nikhil Khadtare (Spring City, PA); Aruna Murty (Newtown, PA); Qun Liu (Skillman, NJ)
Assignee: FB-HRS, LLC
A61K31/18A61K9/4825A61K31/138A61K47/02A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,070
App. No.
18/317,654
Granted
Jan 28, 2025
Kind
B2
Abstract

Described are pharmaceutical compositions in fixed dose combinations containing: a) a dofetilide component; and b) a mexiletine component; wherein the dofetilide component and the mexiletine component are physically separated from each other, along with methods of treating or preventing atrial fibrillation or a symptom associated therewith in a subject in need thereof by administering to the subject such a pharmaceutical composition and methods of preparing such fixed dose combination products.

Claims (78)

1. A pharmaceutical composition in unit dosage form comprising:

a) a dofetilide component; and

b) a mexiletine component;

wherein said dofetilide component and said mexiletine component are contained within a single dosage form;

wherein at least one of the two components chosen from said dofetilide component and said mexiletine component is coated with a coating, and said unit dosage form has an immediate-release profile for said dofetilide component and for said mexiletine component;

wherein said unit dosage form contains one of the following (a), (b) or (c) compositions: (a) about 500 mcg dofetilide and about 275 mg mexiletine hydrochloride, (b) about 500 mcg dofetilide and about 245 mg mexiletine hydrochloride, (c) about 250 mcg dofetilide and about 245 mg mexiletine hydrochloride;

wherein said unit dosage form is a capsule,

wherein said mexiletine component comprises a plurality of pellets, each of said pellets having a pellet core that is uncoated or coated with a pellet coating,

wherein each of said pellet cores comprises a mixture of mexiletine hydrochloride and pellet excipients,

wherein each of said pellet cores contains from about 70% to about 80% by weight of mexiletine hydrochloride and each of said pellet cores contains about 2% by weight of povidone, and wherein said dofetilide component comprises a tablet, said tablet comprises a mixture of dofetilide and tablet excipients, said tablet is uncoated or coated with a tablet coating, and said coated or uncoated tablet contains from about 0.5% to about 0.6% by weight of dofetilide;

wherein said mixture of mexiletine hydrochloride and pellet excipients is a mixture of (i) a blend of mexiletine hydrochloride, a polyvinylpyrrolidone binder, and a first microcrystalline cellulose, with (ii) a second microcrystalline cellulose, colloidal silica and magnesium stearate,

wherein said pellet coating, when said pellet is coated, is a polyvinyl alcohol polymeric film coating, and said pellet coating is present in an amount of about 9.1% by weight of said coated pellet,

wherein said pellet core contains an amount of about 10% by weight of said second microcrystalline cellulose, and said first microcrystalline cellulose and said second microcrystalline cellulose in each of said pellet cores have different particle sizes, and

wherein said tablet coating, when said tablet is coated, is a polyvinyl alcohol polymeric film coating, and said tablet coating is present in an amount of about 9.1% by weight of said coated tablet.

2. The pharmaceutical composition of claim 1 , wherein said at least one of the two components chosen from said dofetilide component and said mexiletine component is compressed.

3. The pharmaceutical composition of claim 1 , wherein said tablet excipients comprise colloidal silica and magnesium stearate.

4. The pharmaceutical composition in unit dosage form of claim 1 ,

wherein said dofetilide component has impurities analyzed over time that satisfy at least one of the three characteristics chosen from the following (a), (b) and (c):

(a) below quantitation limit at room temperature and less than 0.5% under 40° C./75% RH conditions one month after the pharmaceutical composition in unit dosage form was prepared,

(b) less than 0.8% under 40° C./75% RH conditions two months after the pharmaceutical composition in unit dosage form was prepared, and

(c) less than 0.3% at room temperature and less than 1% under 40°° C./75% RH conditions three months after the pharmaceutical composition in unit dosage form; and

wherein said mexiletine component has impurities analyzed over time that satisfy at least one of the three characteristics chosen from the following (d), (e) and (f):

(d) below quantitation limit at room temperature and under 40° C./75% RH conditions one month after the pharmaceutical composition in unit dosage form was prepared,

(e) below quantitation limit under 40° C./75% RH conditions two months after the pharmaceutical composition in unit dosage form was prepared, and

(f) below quantitation limit at room temperature and under 40° C./75% RH conditions three months after the pharmaceutical composition in unit dosage form was prepared.

5. The pharmaceutical composition in unit dosage form of claim 4 ,

wherein said dofetilide component has impurities analyzed over time that satisfy at least one of the three characteristics chosen from the following (a), (b) and (c):

(a) below quantitation limit at room temperature and less than 0.2% under 40° C./75% RH conditions one month after the pharmaceutical composition in unit dosage form was prepared,

(b) less than 0.5% under 40°° C./75% RH conditions two months after the pharmaceutical composition in unit dosage form was prepared, and

(c) less than 0.2% at room temperature and less than 0.7% under 40° C./75% RH conditions three months after the pharmaceutical composition in unit dosage form was prepared; and

wherein said mexiletine component has impurities analyzed over time that satisfy at least one of the three characteristics chosen from the following (d), (e) and (f):

(d) below quantitation limit at room temperature and under 40° C./75% RH conditions one month after the pharmaceutical composition in unit dosage form was prepared,

(e) below quantitation limit under 40° C./75% RH conditions two months after the pharmaceutical composition in unit dosage form was prepared, and

(f) below quantitation limit at room temperature and under 40° C./75% RH conditions three months after the pharmaceutical composition in unit dosage form was prepared.

6. A method of treating or preventing atrial fibrillation or a symptom associated therewith in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 4 .

7. A method of preparing the pharmaceutical composition of claim 4 , comprising: obtaining the dofetilide component and the mexiletine component, and placing the dofetilide component and the mexiletine component within a capsule.

8. The method according to claim 7 , wherein said placing said dofetilide component and said mexiletine component within said capsule comprises filling a gelatin capsule with at least one coated dofetilide tablet and at least one uncoated mexiletine pellet.

9. The method according to claim 7 , wherein said placing the dofetilide component and the mexiletine component within the capsule comprises filling a gelatin capsule with at least one uncoated dofetilide tablet and at least one coated mexiletine pellet.

10. The method according to claim 8 , wherein manufacturing said coated dofetilide tablet comprises

geometrically mixing micronized dofetilide with starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate, yielding a dofetilide blend;

compressing said dofetilide blend, yielding a dofetilide tablet; and

coating said dofetilide tablet with polyvinyl alcohol polymeric film coating yielding a coated dofetilide tablet.

11. The method according to claim 9 , wherein manufacturing said uncoated dofetilide tablet comprises

geometrically mixing micronized dofetilide with starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate, yielding a dofetilide blend; and

compressing said dofetilide blend, yielding an uncoated dofetilide tablet.

12. The method according to claim 8 , wherein manufacturing said uncoated mexiletine pellet comprises

granulating mexiletine hydrochloride with the first microcrystalline cellulose and with the polyvinylpyrrolidone binder yielding a mexiletine granule;

drying said mexiletine granule yielding a dry mexiletine granule;

milling said dry mexiletine granule yielding a milled mexiletine granule;

blending said milled mexiletine granule with the second microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate yielding a mexiletine blend; and

compressing said mexiletine blend yielding an uncoated mexiletine pellet.

13. The method according to claim 9 , wherein manufacturing said coated mexiletine pellet comprises

granulating mexiletine hydrochloride with the first microcrystalline cellulose and with the polyvinylpyrrolidone binder yielding a mexiletine granule;

drying said mexiletine granule yielding a dry mexiletine granule;

milling said dry mexiletine granule yielding a milled mexiletine granule;

blending said milled mexiletine granule with the second microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate yielding a mexiletine blend;

compressing said mexiletine blend yielding a mexiletine pellet; and

coating said mexiletine pellet with polyvinyl alcohol polymeric film coating yielding a coated mexiletine pellet.

14. The method of preparing the pharmaceutical composition of claim 4 , comprising: obtaining the dofetilide component and the mexiletine component, and placing the dofetilide component and the mexiletine component within a capsule,

wherein said placing said dofetilide component and said mexiletine component within said capsule comprises

(a) filling a gelatin capsule with at least one coated dofetilide tablet and at least one uncoated mexiletine pellet,

wherein manufacturing said coated dofetilide tablet comprises geometrically mixing micronized dofetilide with starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate, yielding a dofetilide blend;

compressing said dofetilide blend, yielding a dofetilide tablet; and

coating said dofetilide tablet with polyvinyl alcohol polymeric film coating yielding a coated dofetilide tablet; and

wherein manufacturing said uncoated mexiletine pellet comprises granulating mexiletine hydrochloride with the first microcrystalline cellulose and with the polyvinylpyrrolidone binder yielding a mexiletine granule;

drying said mexiletine granule yielding a dry mexiletine granule;

milling said dry mexiletine granule yielding a milled mexiletine granule;

blending said milled mexiletine granule with the second microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate yielding a mexiletine blend; and

compressing said mexiletine blend yielding an uncoated mexiletine pellet; or

(b) filling a gelatin capsule with at least one uncoated dofetilide tablet and at least one coated mexiletine pellet,

wherein manufacturing said uncoated dofetilide tablet comprises geometrically mixing micronized dofetilide with starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate, yielding a dofetilide blend; and

compressing said dofetilide blend, yielding an uncoated dofetilide tablet; and

wherein manufacturing said coated mexiletine pellet comprises granulating mexiletine hydrochloride with the first microcrystalline cellulose and with the polyvinyl pyrrolidone binder yielding a mexiletine granule;

drying said mexiletine granule yielding a dry mexiletine granule;

milling said dry mexiletine granule yielding a milled mexiletine granule;

blending said milled mexiletine granule with the second microcrystalline cellulose; colloidal silicon dioxide and magnesium stearate yielding a mexiletine blend;

compressing said mexiletine blend yielding a mexiletine pellet; and

coating said mexiletine pellet with polyvinyl alcohol polymeric film coating yielding a coated mexiletine pellet.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2023
From: KHADTARE, NIKHIL; MURTY, ARUNA; LIU, QUN
To: FB-HRS, LLC
Reel/Frame 063646/0031 →
Continuity (3)
Continuation PCTUS2021072467 · Nov 17, 2021
Provisional Application 63115258 · Nov 18, 2020
Related Publication 20230381123A1 · Nov 30, 2023
References Cited (35)
US 3659019A · Koppe · 1972 [cited by examiner]
US 6805881B1 · Kanikanti · 2004 [cited by examiner]
US 9597302B1 · Yan et al. · 2017 [cited by applicant]
US 20020098232A1 · Midha · 2002 [cited by examiner]
US 20060024352A1 · Poxon · 2006 [cited by examiner]
US 20060246134A1 · Venkatesh · 2006 [cited by examiner]
US 20090253801A1 · Shah et al. · 2009 [cited by applicant]
US 20100104637A1 · Qiu · 2010 [cited by examiner]
US 20110071135A1 · Chase · 2011 [cited by examiner]
US 20170266115A1 · Appel · 2017 [cited by examiner]
US 20190240158A1 · Yenkar · 2019 [cited by examiner]
CN 101032462A · 2007 [cited by applicant]
WO 2012010977A2 · 2012 [cited by applicant]
Guo, Yutao et al. “Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation,” Chest vol. 147, issue 1 (2015) pp. 109-119. [cited by applicant]
Chei, Choy-Lye et al. “Prevalence and Risk Factors of Atrial Fibrillation in Chinese Elderly: Results from the Chinese Longitudinal Healthy Longevity Survey,” Chinese Medical Journal, vol. 128, issue 18 (Sep. 20, 2015) … [cited by applicant]
Chugh, Sumeet S. et al. “Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study,” Circulation, vol. 129, issue 8 (Feb. 25, 2014) pp. 837-847. [cited by applicant]
Colilla, Susan et al. “Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population,” American Journal of Cardiology, vol. 112, issue 8 (Oct. 15, 2013) pp. 1142-1147. [cited by applicant]
Suttorp, Maarten J., et al. “Efficacy and safety of a new selective class Ill antiarrhythmic agent Dofetilide in paroxysmal atrial fibrillation or atrial flutter,” American Journal of Cardiology, vol. 69, issue 4 (Feb. … [cited by applicant]
Rasmussen, H. S., et al. “Dofetilide, A Novel Class III Antiarrhythmic Agent,” Journal of Cardiovascular Pharmacology, vol. 20, suppl. 2 (1992) pp. S96-S105. [cited by applicant]
Zimetbaum, Peter “Antiarrhythmic drug therapy for atrial fibrillation,” Circulation, vol. 125, issue 5 (2012) pp. 381-389. [cited by applicant]
Qin, Dingxin et al. “Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation,” Journal of Cardiology, vol. 67, issue 5 (2016) pp. 471-476. [cited by applicant]
Aktas, Mehmet K., et al. “Dofetilide-induced long QT and torsades de pointes,” Annals of Noninvasive Electrocardiology, vol. 12, issue 3 (Jul. 2007) pp. 197-202. [cited by applicant]
Qi, Datun et al. “Heterogeneous distribution of INa-L determines interregional differences in rate adaptation of repolarization,” Heart Rhythm, vol. 12, issue 6 (Jun. 2015) pp. 1295-1303. [cited by applicant]
Badri, Marwan et al. “Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures,” JACC: Clinical Electrophysiology, vol. 1, issue 4 (Aug. 2015) pp. 315-322. [cited by applicant]
Yan, Gan-Xin et al. “Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: Direct evidence from intracellular recordings in the intact left ventricular wall,… [cited by applicant]
Talbot, R. G., et al. “Treatment of ventricular arrhythmias with mexiletine (Ko 1173),” Lancet (Aug. 25, 1973) pp. 399-404. [cited by applicant]
Campbell, N. P. S. et al. “Mexiletine (Ko 1173) in the management of ventricular dysrhythmias,” Lancet (Aug. 25, 1973) pp. 404-407. [cited by applicant]
January, Craig T. et al. “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on pr… [cited by applicant]
Gupta, Yogendra Kumar et al. “Fixed dose drug combinations: Issues and challenges in India,” Indian Journal of Pharmacology, vol. 48, issue 4 (2016) pp. 347-349. [cited by applicant]
International Search Report (Form PCT/ISA/210) for International Patent Application No. PCT/US2021/072467, issued from the International Searching Authority, date of mailing Jun. 9, 2022, 3 pages. [cited by applicant]
Written Opinion of the International Searching Authority (Form PCT/ISA/237) for International Patent Application No. PCT/US2021/072467, issued from the International Searching Authority, date of mailing Jun. 9, 2022, 6 … [cited by applicant]
Miller J M, Zipes D P. Therapy for Cardiac Arrhythmias. In: Mann D. L., Zipes D. P., Libby P., Bonow J. O. (eds) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier Publisher. 2014: 693. [cited by applicant]
Muhammad Abubakar Shakir, et al, “Combination Therapy with Dofetilide and Mexiletine for Atrial Fibrillation: Increased Efficacy and Decreased QT Interaval Prolongation,” ACC.20, World Congress of Cardiology, JACC Mar. … [cited by applicant]
Muhammad Shakir, et al, “Mexiletine: A Treatment for all Cause Acquired QT Interval Prolongation,” ACC.20, World Congress of Cardiology, JACC Mar. 24, 2020, vol. 75, Issue 11 (1 pages). [cited by applicant]
Farah Olleik, et al, “Mexiletine: Antiarrythmic mechanisms, emerging clinical applications and mortality,” Pacing Clinical Electrophysiol. vol. 1-9, 2023. [cited by applicant]
Cited By (1)
US 12,576,074